Abstract
ADCs comprise three essential components: a monoclonal antibody, a linker, and a payload, which collectively target cancer cells with precision. Central to ADC innovation is the strategic selection and optimization of payloads. These cytotoxic payloads, ranging from microtubule inhibitors to DNA damage molecules, deliver the therapeutic effect but require careful balancing to ensure both efficacy and an acceptable safety profile.
Through this webinar, we will delve into the diverse characteristics of payloads and introduce anti-payload antibodies as indispensable analytical tools. By leveraging these tools, we aspire to unlock the full potential of ADCs in tackling the multifaceted challenges posed by cancer.
Key Content
1. ADCs Overview
2. Significance and Characteristics of ADC Payloads
3. A thorough understanding of the PK and PD properties of ADCs is pivotal to their success
4. Anti-payload antibodies serve as invaluable tools in assessing the safety and efficacy of ADC drugs